CSTL Stock Cash Flow Statements

Castle Biosciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Castle Biosciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30

operating activities
net income	4,523,000	-25,848,000	9,590,000	2,269,000	8,920,000	-2,534,000	-2,580,000	-6,905,000	-18,777,000	-29,204,000	-20,618,000	-20,249,000	-1,648,000	-24,623,000	-6,430,000	-11,791,000	-8,791,000	-4,280,000	-4,889,000	-4,589,000	-1,376,000	570,000	2,054,767	5,849,295
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	3,414,000	29,764,000	5,768,000	3,541,000	3,348,000	3,340,000	3,224,000	3,174,000	3,040,000	2,892,000	2,841,000	2,923,000	2,628,000	2,151,000	1,451,000	1,089,000
stock-based compensation expense	11,208,000	11,179,000	11,439,000	13,027,000	13,179,000	12,675,000	11,802,000	13,043,000	12,849,000	13,525,000	9,923,000	9,196,000	8,783,000	8,419,000
change in fair value of trading securities	-1,185,000	1,425,000
deferred income taxes	-4,667,000	-770,000	-2,307,000	5,250,000			-236,000	0	0	13,000	-38,000	0	-1,962,000	123,000
accretion of discounts on marketable investment securities	-1,171,000	-1,435,000	-1,613,000	-1,650,000	-1,723,000	-1,699,000	-1,640,000	-1,569,000	-1,053,000	-1,229,000	-1,184,000
other	189,000	30,000	60,000	125,000	-96,000	179,000	351,000	71,000	2,000	211,000	-28,000	147,000	27,000	12,000		-168,000	36,000	33,000	-19,000					0
change in operating assets and liabilities:
accounts receivable	3,910,000	-5,217,000	-769,000	-4,254,000	-3,358,000	-4,262,000	-1,151,000	-5,801,000	-3,595,000	-4,383,000	-540,000	-50,000	-2,903,000	-2,725,000	1,456,000	-812,000	-3,717,000	-1,558,000	-192,000	-482,000	2,176,000	161,000	-1,696,598	-2,824,715
prepaid expenses and other current assets	-1,332,000	-3,364,000	537,000	-1,385,000	-191,000	-103,000	457,000	-1,050,000	812,000	-654,000	646,000	-1,163,000	-350,000	-357,000	1,351,000	-2,081,000	-332,000	1,679,000	-1,048,000	-2,001,000	363,000	-129,000	245,673	-1,422,350
inventory	-1,517,000	1,286,000	-1,563,000	1,441,000	-368,000	297,000	-2,173,000	352,000	-1,601,000	-540,000	-178,000	-436,000	-737,000	-329,000	355,000	-251,000	316,000	-93,000	-538,000	-12,000	-449,000	19,000	-415,575	-270,764
operating lease assets	244,000	420,000	320,000	324,000	340,000	338,000	332,000	-121,000	-800,000	331,000	297,000	257,000	215,000	222,000
other assets	25,000	-38,000	297,000	-178,000	373,000	-230,000	125,000	-375,000	-399,000	319,000	85,000	29,000	462,000	42,000	13,000	-98,000	130,000	-225,000	102,000	-1,441,000	15,000	-77,000	-64,744	-8,199
accounts payable	1,074,000	615,000	-570,000	-2,152,000	-1,228,000	-422,000	3,014,000	-378,000	-825,000	3,896,000	-1,573,000	1,853,000	115,000	187,000	-855,000	1,356,000	-643,000	-40,000	-42,000	-233,000	388,000	56,000	603,932	477,097
operating lease liabilities	-343,000	-526,000	-426,000	-431,000	-182,000	-250,000	-241,000	135,000	1,026,000	-68,000	-49,000	-114,000	-219,000	-226,000
accrued compensation	7,116,000	-14,698,000	4,883,000	6,433,000	6,531,000	-14,237,000	6,540,000	5,107,000	4,502,000	-11,562,000	4,826,000	4,682,000	5,904,000	-6,917,000	3,196,000	3,535,000	3,376,000	-3,899,000	2,754,000	1,702,000	1,518,000	-2,645,000	2,102,847	891,418
other accrued and current liabilities	-667,000	1,141,000	-726,000	978,000	-5,000	73,000	763,000	-671,000	1,033,000	1,014,000
net cash from operating activities	20,821,000	-6,036,000	24,365,000	23,338,000	23,998,000	-6,835,000	18,587,000	5,012,000	-3,786,000	-25,439,000	-6,000,000	-5,224,000	-9,001,000	-21,430,000	-2,781,000	-6,133,000	-6,438,000	-3,631,000	-430,000	-2,955,000	13,501,000	-251,000	4,493,260	751,542
capex	-9,263,000	-4,740,000	-7,567,000	-6,378,000	-5,229,000	-9,152,000	-3,793,000	-2,455,000	-4,035,000	-608,000	-1,787,000	-2,038,000	-1,405,000	-370,000	-893,000	-740,000	-1,130,000	-530,000	-563,000	-1,906,000	-1,756,000	-500,000	-347,336	-165,191
free cash flows	11,558,000	-10,776,000	16,798,000	16,960,000	18,769,000	-15,987,000	14,794,000	2,557,000	-7,821,000	-26,047,000	-7,787,000	-7,262,000	-10,406,000	-21,800,000	-3,674,000	-6,873,000	-7,568,000	-4,161,000	-993,000	-4,861,000	11,745,000	-751,000	4,145,924	586,351
investing activities
purchases of marketable investment securities	-44,401,000	-48,431,000	-47,320,000	-45,215,000	-52,440,000	-60,754,000	-52,382,000	-50,255,000	-56,355,000	-30,083,000	-2,881,000
proceeds from maturities of marketable investment securities	44,000,000	36,300,000	60,650,000	36,800,000	36,250,000	50,200,000	48,500,000	43,000,000	45,000,000	50,000,000
purchases of debt securities classified as held-to-maturity	0	-5,569,000
asset acquisition, net of cash and cash equivalents acquired
purchases of property and equipment	-9,263,000	-4,740,000	-7,567,000	-6,378,000	-5,229,000	-9,152,000	-3,793,000	-2,455,000	-4,035,000	-3,338,000	-1,787,000	-2,038,000	-1,405,000	-402,000	-893,000	-927,000	-913,000	-750,000	-589,000	-1,906,000	-1,756,000	-500,000	-347,336	-165,191
proceeds from sale of property and equipment	12,000	9,000	7,000	4,000	2,000	5,000	3,000	2,000	3,000	5,000	186,000	1,000			4,000	4,000			1,000
net cash from investing activities	-28,378,000	-22,431,000	5,770,000	-14,789,000	-21,417,000	-19,701,000	-7,672,000	-9,708,000	-15,387,000	16,584,000	-4,482,000	-134,150,000	-27,511,000	-402,000	-30,889,000	-923,000	-34,095,000	-750,000	-588,000	-1,904,000	-1,756,000	-500,000	-347,336	-165,191
financing activities
proceeds from exercise of common stock options	19,000	18,000	373,000	1,571,000	8,000	65,000	72,000	13,000	89,000	95,000	158,000	166,000	110,000	399,000	366,000	1,523,000	1,354,000	991,000	901,000	292,000	329,000	71,000	10,454	745,996
payment of employees’ taxes on vested restricted stock units	-589,000	-2,515,000	-6,379,000	-1,294,000	-615,000	-474,000	-4,015,000	-271,000	-534,000	-314,000	-1,554,000	-46,000	-32,000	-56,000
proceeds from contributions to the employee stock purchase plan	512,000	970,000	647,000	585,000	660,000	1,089,000	682,000	339,000	706,000	982,000	680,000	301,000	614,000	897,000	549,000	371,000	537,000	855,000	408,000	384,000	335,000	488,000
repayment of principal portion of finance lease liabilities	-31,000	-26,000	-26,000	-24,000	-11,000	-36,000	-36,000	-36,000	-35,000	-35,000	-34,000	-33,000	-31,000	-24,000
proceeds from lease incentives received
proceeds from issuance of term debt			0	0	0	10,000,000
net cash from financing activities	101,000	-1,553,000	-5,385,000	838,000	42,000	10,644,000	-3,297,000	45,000	226,000	728,000	-750,000	388,000	661,000	1,216,000	126,000	1,894,000	1,891,000	1,510,000	227,820,000	8,150,000	69,361,000	559,000	223,770	76,420,001
net change in cash and cash equivalents		-30,020,000		9,387,000	2,623,000	-15,892,000		-4,651,000	-18,947,000	-8,127,000			-35,851,000	-20,616,000		-5,162,000	-38,642,000	-2,871,000	226,802,000	3,291,000	81,106,000	-192,000	4,369,694	77,006,352
beginning of period		119,709,000		0	0	98,841,000		0	0	122,948,000			0	329,633,000		0	0	409,852,000		0	0	98,845,000	488	0
end of period		89,689,000		9,387,000	2,623,000	82,949,000		-4,651,000	-18,947,000	114,821,000			-35,851,000	309,017,000		-5,162,000	-38,642,000	406,981,000		3,291,000	81,106,000	98,653,000	4,370,182	77,006,352
change in fair value of contingent consideration											-300,000	-151,000	-20,398,000	2,562,000
acquisition of business, net of cash and cash equivalents acquired											0	-305,000
asset acquisitions, net of cash and cash equivalents acquired
net changes in cash and cash equivalents
beginning of year
end of year
asset acquisition, adjustment to purchase price
disclosure of non-cash investing and financing activities:
accrued purchases of property and equipment										2,730,000				32,000		187,000	-217,000	220,000	26,000
deferred acquisition costs														1,026,000
property and equipment acquired with tenant improvement allowance										89,000									0
medicare advance payment															-2,999,000	-3,178,000			0	0
other liabilities
payment of common stock offering costs															0	0	0	-336,000
other accrued liabilities												-1,964,000	1,082,000	29,000	1,667,000	925,000	24,000	-330,000	-1,148,000	1,446,000	359,000	-96,000	617,263	-639,885
asset acquisition												0				0
amortization of debt discounts and issuance costs																			173,000	214,000	228,000	224,000	234,379	440,657
loss on extinguishment of debt
proceeds from public offerings of common stock, net of underwriting discounts, commissions and offering costs																			250,537,000
repayment of term debt
stock compensation expense																5,210,000	4,766,000	4,913,000		2,118,000	1,653,000	1,577,000	712,287	229,484
deferred rent and other liabilities																131,000	-64,000	-64,000	-101,000	201,000
proceeds from public offering of common stock, net of underwriting discounts, commissions and offering costs
repayments on term debt																				-2,500,000
common stock offering costs incurred but not paid
depreciation																		233,000	160,000	119,000	102,000	91,000	99,688	91,027
amortization of intangibles																							-167	0
other non-cash interest																							-176
gain on extinguishments of debt
change in fair value of preferred stock warrant liability																							-24	532,910
change in fair value of embedded derivative																							-199	100,738
change in fair value of convertible promissory note accounted for under the fair value option																							232
proceeds from exercise of preferred stock warrants
proceeds from issuance of convertible promissory notes (including 4,756 from related parties for the year ended december 31, 2019), net of issuance costs
proceeds from issuance of convertible promissory note and common stock warrant, net of issuance costs																							256
proceeds from issuance of term debt, net of issuance costs																							-145	0
repayments on line of credit																							145	0
supplemental disclosure of cash paid (refunded) for:
interest																								542,648
income taxes																								0
issuance of common stock upon conversion of convertible preferred stock
conversion of preferred stock warrants to common stock warrants
issuance of common stock upon conversion of convertible promissory notes
cashless exercise of common stock warrants
gain on extinguishment of debt																							431
proceeds from issuance of preferred stock and preferred stock warrants																							-17
proceeds from issuance of convertible promissory notes (including 4,756 from related parties for the nine months ended september 30, 2019), net of issuance costs
common stock and debt issuance costs incurred but not paid
proceeds from issuance of convertible promissory notes (including 4,756 from related parties for the six months ended june 30, 2019), net of issuance costs
payments of deferred offering costs
deferred rent liability																						-2,000	-419	-684
investing activites
proceeds from issuance of convertible promissory notes (including 4,756 from related parties for the three months ended march 31, 2019), net of issuance costs
accrued capital expenditures																						270,000
initial public offering costs incurred but not paid
proceeds from initial public offering of common stock, net of underwriting discounts, commissions and issuance costs																							-4,428
proceeds from issuance of term debt and preferred stock warrants, net of issuance costs
proceeds from issuance of convertible promissory notes (including 4,756 from related parties), net of issuance costs
proceeds from line of credit
proceeds from issuance of convertible promissory notes (including 4,755,882 from related parties), net of issuance costs																								0
payment of deferred offering costs
deferred offering costs and debt issuance costs incurred but not paid

We provide you with 20 years of cash flow statements for Castle Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Castle Biosciences stock. Explore the full financial landscape of Castle Biosciences stock with our expertly curated income statements.

The information provided in this report about Castle Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.